This educational program consists of three presentations on management of patients with CKD.

This course consists of the following:

• Diagnosis and Guidelines - What is the rationale for SGLT2i? - Janaka Karalliedde, MD, PhD - London, United Kingdom
• Initiating therapy - What are the practical challenges with SGLT2i therapy? - Alice Cheng, MD - Toronto, Canada
• Follow up - Defining treatment goals, a shift in paradigm? - Prof. Peter Rossing, MD - Copenhagen, Denmark

After watching these three videos, the learner should be able to:

• Discuss the cardioprotective and reno-protective effects of SGLT2i
• Recall the treatment algorithm for the management of T2DM in patients with CKD in the EASD-ADA Guidelines
• Describe practical considerations and challenges around initiation of SGLT2i therapy
• Explain the rationale behind the recommended treatment algorithm for patients with T2DM and CKD in the KDIGO Diabetes Management in CKD guidelines

Expert faculty

• Janaka Karalliedde, MD, PhD - London, United Kingdom
• Alice Cheng, MD - Toronto, Canada
• Prof. Peter Rossing, MD - Copenhagen, Denmark

Target audience

This educational activity is designed for cardiologists, internists, nephrologists in secondary care and other healthcare professionals with an interest in management of patients with CKD.

CME accreditation

This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by unrestricted educational grants from Boehringer Ingelheim/Lilly.